Atea Pharmaceuticals, Inc. (AVIR) Net Income (Loss) Attributable to Parent USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Atea Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • Atea Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$63.2 M, a 78.1% decline year-over-year.
  • Atea Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$164 M, a 49.7% decline year-over-year.
  • Atea Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$136 M, a 17.3% decline from 2022.
  • Atea Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$116 M, a 196% decline from 2021.
  • Atea Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $121 M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$164 M -$63.2 M -$27.7 M -78.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$136 M -$39.2 M -$4.73 M -13.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$131 M -$33.1 M -$25.1 M -311% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$106 M -$28.2 M +$3.15 M +10.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-08
Q1 2023 -$109 M -$35.5 M +$6.61 M +15.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$116 M -$34.4 M -$152 M -129% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $35.7 M -$8.07 M +$20.1 M +71.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $15.5 M -$31.3 M -$32.9 M -2136% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 $48.4 M -$42.1 M -$72.8 M -237% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 $121 M $117 M +$96.5 M +467% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $24.7 M -$28.2 M -$10.6 M -60% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $35.3 M $1.54 M +$11.5 M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 $23.8 M $30.7 M +$34.7 M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$10.9 M $20.7 M +$25.3 M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$36.3 M -$17.6 M -$14 M -385% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$22.3 M -$9.99 M -$6.44 M -181% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$15.8 M -$3.99 M -$1.8 M -81.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$14 M -$4.66 M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$3.63 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-12-10
Q2 2019 -$3.55 M Apr 1, 2019 Jun 30, 2019 10-Q 2020-12-10
Q1 2019 -$2.19 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-12-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.